Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

NCT04158739 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04158739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04158739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial of the CD123 X CD3 DART Molecule Flotetuzumab (NSC#808294) in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Children's Oncology Group
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 22, 2020
Completion date
March 31, 2027
Enrollment
16 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent acute myeloid leukemia, refractory acute myeloid leukemia